ADELAIDE, Australia / RankWire.AI / – Research conducted by Australian scientists has pinpointed a molecular switch that controls the dissemination of aggressive tumors, offering a new avenue for therapy to prevent the development of secondary cancers. Published in EMBO Molecular Medicine, the study from Adelaide University and the Olivia Newton-John Cancer Research Institute showed that restoring the regulatory molecule miR-342 significantly diminishes tumor spread. The research indicates a promising new method to confront triple-negative breast cancer by targeting dormant cancer cells before they form life-threatening secondary lesions in distant organs.
Triple-negative breast cancer makes up 10% to 15% of Australia’s roughly 21,000 breast cancer diagnoses each year but accounts for a higher proportion of fatalities. This subtype lacks estrogen, progesterone, and HER2 receptors, which renders standard hormone-targeted treatments ineffective. The lead researchers demonstrated that a reduction in miR-342 levels causes overactivation of a cancer-promoting pathway called E2F, enabling dormant cancer cells to spread and develop dangerous secondary tumors throughout the body.
New Therapeutic Strategies Bring Hope for High-Risk Metastasis Prevention
Using pre-clinical models, scientists showed that increasing miR-342 levels markedly decreased the migration of cancer cells to distant sites. In addition, they found that palbociclib, an existing CDK4/6 inhibitor drug approved for hormone receptor-positive breast cancers, significantly suppressed metastatic tumor growth in models with low miR-342. These results suggest that measuring miR-342 could enable clinicians to repurpose current drugs for high-risk patients effectively.
Associate Professor Philip Gregory, co-senior author from Adelaide University’s Centre for Cancer Biology, confirmed that preventing metastasis remains the main challenge in treating aggressive breast cancers. Gregory highlighted that because palbociclib targets the hyperactive E2F pathway, administering the drug after cancer cells have spread can prevent microscopic deposits from enlarging. This approach shifts focus from solely shrinking primary tumors to stopping microscopic secondary cancers from evolving into life-threatening conditions.
Findings in Peer-Reviewed Journal Highlight Potential for Personalized Treatment
The research team emphasized that the biological diversity of triple-negative breast cancer has historically complicated the development of universal targeted therapies. By identifying a specific weakness common to a particular patient subgroup, the study paves the way for individualized treatment strategies. As Australian scientists discover a promising new approach, efforts are underway to validate these findings using patient-derived models ahead of clinical testing.
Medical oncologists and cancer research organizations across Australia have welcomed the new insights, emphasizing the critical need for expanded treatment options when primary therapies are unsuccessful. The research team intends to work with international clinical networks to speed up biomarker screening protocols. Confirming miR-342 testing could soon enable healthcare providers to identify suitable candidates for early targeted therapies with CDK4/6 inhibitors during initial treatment phases.
}#}));